AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has earned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $44.71.

A number of brokerages recently commented on ANAB. JPMorgan Chase & Co. dropped their target price on AnaptysBio from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Monday, April 1st. Stifel Nicolaus began coverage on AnaptysBio in a research report on Wednesday, February 21st. They issued a "buy" rating and a $50.00 target price on the stock. Wedbush raised AnaptysBio from a "neutral" rating to an "outperform" rating and boosted their price target for the company from $20.00 to $34.00 in a report on Tuesday, March 12th. Piper Sandler began coverage on AnaptysBio in a report on Friday, February 16th. They issued an "overweight" rating and a $80.00 price target for the company. Finally, BTIG Research began coverage on AnaptysBio in a report on Monday, February 26th. They issued a "buy" rating and a $55.00 price target for the company.

AnaptysBio Trading Down 1.0 %

Shares of ANAB stock traded down $0.22 during trading hours on Friday, reaching $21.08. 134,088 shares of the company's stock were exchanged, compared to its average volume of 443,492. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $27.50. The stock has a market cap of $564.10 million, a PE ratio of -3.47 and a beta of -0.30. The stock's fifty day moving average price is $23.69 and its two-hundred day moving average price is $20.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping analysts' consensus estimates of ($1.74) by $0.15. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. On average, equities analysts expect that AnaptysBio will post -6.25 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, CEO Daniel Faga sold 3,000 shares of the company's stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares of the company's stock, valued at approximately $16,045,443.54. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Daniel Faga sold 3,000 shares of the business's stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the sale, the chief executive officer now directly owns 749,087 shares in the company, valued at $16,045,443.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 2,180 shares of the company's stock in a transaction on Monday, January 8th. The shares were sold at an average price of $21.81, for a total value of $47,545.80. Following the completion of the sale, the chief financial officer now owns 4,029 shares of the company's stock, valued at $87,872.49. The disclosure for this sale can be found here. Insiders sold a total of 168,605 shares of company stock valued at $3,839,195 in the last three months. 35.50% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

Several large investors have recently added to or reduced their stakes in ANAB. Quantbot Technologies LP purchased a new stake in AnaptysBio in the 2nd quarter valued at $34,000. Tower Research Capital LLC TRC grew its holdings in AnaptysBio by 248.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company's stock valued at $65,000 after buying an additional 2,565 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company's stock valued at $66,000 after buying an additional 2,390 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of AnaptysBio by 75.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company's stock worth $101,000 after purchasing an additional 2,142 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of AnaptysBio by 134.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company's stock worth $106,000 after purchasing an additional 3,381 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.